Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Update on therapeutic neovascularization.

Yihai Cao1, An Hong, Henny Schulten

  • 1Laboratory of Angiogenesis Research, Microbiology and Tumor Biology Center, Karolinska Institutet, S-171 77 Stockholm, Sweden. yihai.cao@mtc.ki.se

Cardiovascular Research
|January 25, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Biomimetic Amelogenin-Fibronectin Fusion Protein with Dual Cell-Adhesive and Osteoinductive Functions for Alveolar Bone Defect Repair.

Bioengineering (Basel, Switzerland)·2026
Same author

An Inhibitory Aptamer Against PDGF-C Overcomes Anti-VEGF Refractoriness and Reduces Choroidal Neovascularization and Fibrosis.

Investigative ophthalmology & visual science·2026
Same author

Mechanisms of Pericyte-Mediated Cancer Metastasis.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Connective tissue growth factor contributes to resistance to anti-angiogenic therapies in renal cancer.

Theranostics·2026
Same author

Histone H3K27 acetylation of slc25a4 mediates triclocarban-induced transgenerational developmental toxicity in zebrafish (Danio rerio) at subthreshold exposure.

Environmental research·2026
Same author

Integrated Multi-Omics and Spatial Transcriptomics Identify FBLL1 as a Malignant Transformation Driver in Hepatocellular Carcinoma.

Cells·2026
Same journal

YAP plays a critical role in myocardial recovery from myocarditis by suppressing IFN-γ signaling pathway.

Cardiovascular research·2026
Same journal

Metabolic crisis and TRPM4 activation cause QT prolongation in TANGO2 deficiency disorder.

Cardiovascular research·2026
Same journal

Personalizing Atrial Fibrillation Therapy: Moving from Genetic Association to Mechanistic Translation.

Cardiovascular research·2026
Same journal

Placental Growth Factor Promotes Endothelial Activation and Inflammatory Remodelling in Pulmonary Hypertension.

Cardiovascular research·2026
Same journal

Endothelial-to-mesenchymal transition (EndMT) in atherosclerosis: mechanisms, models and therapies.

Cardiovascular research·2026
Same journal

The gut-heart axis in cardio-oncology.

Cardiovascular research·2026
See all related articles

Therapeutic neovascularization shows promise for cardiovascular ischemia. Future strategies may involve combinations of growth factors or cell therapies, or optimized single growth factor treatments for stable, functional vessels.

Area of Science:

  • Cardiovascular Research
  • Regenerative Medicine
  • Angiogenesis Research

Background:

  • Therapeutic neovascularization for cardiovascular ischemia faces challenges despite early promise.
  • Understanding the pleiotropic effects of angiogenic cytokines is crucial.
  • Existing clinical trials have yielded disappointing results.

Purpose of the Study:

  • To review current understanding and future directions in therapeutic neovascularization.
  • To explore novel strategies beyond current clinical limitations.
  • To highlight the importance of preclinical data in guiding therapeutic development.

Main Methods:

  • Review of recent scientific literature on growth factors and pro-angiogenic strategies.
  • Analysis of emerging therapeutic approaches, including combination therapies and single growth factor treatments.

Related Experiment Videos

  • Discussion of gene therapy versus protein therapy considerations.

    • Main Results:

    • Emerging data suggest single growth factor therapy can yield stable, functional vessels with appropriate dosing and regimens.
    • Combination therapies (growth factors, cell transplants) show potential but increase study complexity.
    • Technical advancements in vector design and slow-release formulations are key.

    Conclusions:

    • Future therapeutic neovascularization strategies require rational design based on fundamental and preclinical data.
    • Optimized single growth factor therapies and combination approaches warrant further investigation.
    • Gene or protein therapy optimization depends on technical progress.